Affiliation:
1. Department of Cardiology, University Hospital Limerick, Dooradoyle, Ireland
Abstract
Transcatheter aortic valve implantation (TAVI) is the usual technique for patients with severe aortic stenosis who are at high risk for surgical aortic valve replacement. The transfemoral (TF) route is the most commonly used access type, and significant progress in this procedure has greatly increased the proportion of patients who can undergo it. Not all patients are suitable for TF TAVI, however, so other routes, including transapical, transaortic, subclavian, trans-subclavian/transaxillary, transcarotid and transcaval, may need to be used. Evidence on these routes shows promising results but the majority of this is registry data rather than randomised controlled trials, so TF TAVI remains the safest access route and should be considered for most patients. However, in patients who are unsuitable for TF TAVI, alternative access routes are safe and feasible. The challenges concern choosing the best route, the valve to use and skill of the specialist centre. This article provides a overview of options for alternative vascular access in TAVI, the clinical rationale for using them, current evidence and areas for clinical investigation.
Reference35 articles.
1. 1. Siontis GC, Praz F, Pilgrim T, et al. Transcatheter aortic valve implantation vs surgical aortic valve replacement for treatment of severe aortic stenosis: a meta-analysis of randomized trials. Eur Heart J 2016;37:3503-12. https://doi. org/10.1093/eurheartj/ehw225; PMID: 27389906.
2. 2. Thyregod HG, Søndergaard L, Ihlemann N, et al. The Nordic Aortic Valve Intervention (NOTION) trial comparing transcatheter versus surgical valve implantation: study protocol for a randomised controlled trial. J Am Coll Cardiol 2015;65:2184-94. https://doi.org/10.1016/j.jacc.2015.03.014; PMID: 25787196.
3. 3. Natarajan D, Makkar R, MacCarthy P, et al. Placement of Aortic Transcatheter Valves (PARTNER) 2 Cohort A trial - transcatheter or surgical aortic-valve replacement in intermediate-risk patients. EuroIntervention 2016;12:805-8. https://doi.org/10.4244/EIJV12I6A131; PMID: 27542796.
4. 4. Barker CM, Reardon MJ. The CoreValve US pivotal trial. Semin Thorac Cardiovasc Surg 2014;26:179-86. https://doi.org/10.1053/ j.semtcvs.2014.10.001; PMID: 25527011.
5. 5. Reardon MJ, Van Mieghem NM, Popma JJ, et al. Surgical or transcatheter aortic-valve replacement in intermediate- risk patients. N Engl J Med 2017;376:1321-31. https://doi. org/10.1056/NEJMoa1700456; PMID: 28304219.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献